Mechanisms and Consequences of Drug-Drug Interactions

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Volumn , Issue , 2008, Pages 879-917

  Farkas, Dora ^a   Shader, Richard I ^a   von Moltke, Lisa L ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ATP binding cassette transporters (ABCs); Mechanism based inhibitors; Over the counter (OTC) medications

Indexed keywords

EID: 85014512948     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch25     Document Type: Chapter

References (199)

1. Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Clin and Exp Allergy 1999;29(Suppl 3):212-216.
2. Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;35:1004-1009.
3. Hanlon JT, Fillenbaum GG, Ruby CM, Gray S, Bohannon A. Epidemiology of over-the-counter drug use in community dwelling elderly:United States perspective. Drugs Aging 2001;18:123-131.
4. Nix DE, Di Cicco RA, Miller AK, Boyle DA, Boike SC, Zariffa N, Jorkasky DK, Schentag JJ. The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. J Clin Pharmacol 1999;39:855-865.
5. Anantharaju A, Feller A, Chedid A. A ging liver. A review. Gerontology 2002;48:343-353.
6. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology:Why are they important and can they be minimized? Crit Rev Oncol/Hematol 2005;55:117-142.
7. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-413.
8. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA. Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121-129.
9. Greenblatt DJ, Patki KC, von Moltke L L, Shader RI. Drug interactions with grapefruit juice:an update. J Clin Psychopharmacol 2001;21:357-359.
10. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction:comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14-23.
11. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644-648.
12. Hidaka M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004;32:581-583.
13. Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli WE. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid Cremophor EL. Br J Clin Pharmacol 2002;53:576-581.
14. Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-405.
15. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-g lycoprotein lead to drug-drug interactions? Toxicol Lett 2005;156:319-329.
16. Ochs HR, Steinhaus E, Locniskar A, Knüchel M, Greenblatt DJ. Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. Klin Wochenschrift 1982;60:411-415.
17. Venkatakrishnan K, Shader RI, Greenblatt DJ. Concepts and mechanisms of drug disposition and drug interactions. In Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W, Eds. Drug Interactions in Psychiatry. Philadelphia:Lippincott Williams & Wilkins; 2005, pp 1-46.
18. Kato R, Ueno K, Imano H, Kawai M, Kuwahara S, Tsuchishita Y, Yonezawa E, Tanaka K. Impairment of ciprofloxacin absorption by calcium polycarbophil. J Clin Pharmacol 2002;42:806-811.
19. Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J Clin Pharmacol 1982;22:259-263.
20. MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989;16:65-73.
21. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety 1995;12:227-233.
22. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005;45:127-132.
23. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121.
24. 13 C]warfarin pseudoracemates in man. J Clin Invest 1980;65:746-753.
25. Banfield C, O'Reilly R, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man:further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983;16:669-675.
26. Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-128.
27. Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs 1977;13:24-34.
28. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions:application and clinical value of in vitro models. Curr Drug Metab 2003;4:423-459.
29. i /AUC) ratios. Drug Metab Dispos Biol Fate Chem 2004;32:1201-1208.
30. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monitor 1996;18:60-64.
31. Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, de Vries R, Kaneko S. Significant pharmacokinetic interaction between risperidone and carbamazepine:its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162:50-54.
32. Parkinson A. Biotransformation of xenobiotics. In Klaassen C, Ed. Casarett & Doull's Toxicology. New York:McGraw-Hill; 1996, pp 113-186.
33. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-1227.
34. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-1106.
35. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
36. Baciewicz AM, and Baciewicz FA Jr. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993;153:1970-1976.
37. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-482.
38. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 2001;7:1221-1229.
39. Hughes H, Biehl J, Jones A, Schmidt L. Metabolism of isoniazid in man as related to the occurence of peripheral neuritis. Am Rev Tuberculosis 1954;70:266-273.
40. Farkas D, Tannenbaum SR. In vitro methods to study chemically-induced hepatotoxicity:a literature review. Curr Drug Metab 2005;6:111-125.
41. Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001;9:442-451.
42. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003;33(Suppl 2):23-30.
43. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6(CYP2D6):clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
44. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9:drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005;45:477-494.
45. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004;5:415-442.
46. Alfaro CA, Piscitelli SC. Drug interactions. In Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP. eds. Principles of Clinical Pharmacoglogy. Boston:Academic Press; 2001, pp 167-180.
47. Ma Q, Lu AY. Origins of individual variability in P4501A induction. Chem Res Toxicol 2003;16:249-260.
48. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos Biol Fate Chem 2001;29:1454-1459.
49. Cao H, Hegele RA. Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. J Hum Genet 2000;45:92-93.
50. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions:what determines individual variability in cytochrome P450 induction? Drug Metab Dispos Biol Fate Chem 2005;33:603-613.
51. Chang TK, Bandiera SM, Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver:interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos Biol Fate Chem 2003;31:7-10.
52. Kerb R, Aynacioglu AS, Brockmöller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C, Ongen HZ, Guzelbey P, Roots I, Brinkmann U. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001;1:204-210.
53. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
54. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Design 2004;10:1295-1312.
55. Chandra P, Brouwer KL. The complexities of hepatic drug transport:current knowledge and emerging concepts. Pharm Res 2004;21:719-735.
56. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R. Digoxin-cyclosporin A interaction:modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-1619.
57. Saito T, Zhang ZJ, Tokuriki M, Ohtsubo T, Shibamori Y, Yamamoto T, Saito H. Cyclosporin A inhibits the extrusion pump function of P-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin. Brain Res 2001;901:265-270.
58. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68:231-237.
59. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
60. Hughes CS, Vaden SL, Manaugh CA, Price GS, Hudson LC. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J Neuro-Oncol 1998;37:45-54.
61. Kang W, Weiss M. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin. Pharm Res 2001;18:1535-1541.
62. Kramer WG, Reuning RH. Use of area under the curve to estimate absolute bioavailability of digoxin. J Pharm Sci 1978;67:141-142.
63. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55:53-81.
64. Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev 1997;27:215-233.
65. Szabo K, Welker E, Bakos E, Müller M, Roninson I, Varadi A, Sarkadi B. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem 1998;273:10132-10138.
66. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997;250:130-137.
67. Ayesh S, Shao YM, Stein WD. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1996;1316:8-18.
68. Fardel O, Lecureur V, Corlu A, Guillouzo A. P-glycoprotein induction in rat liver epithelial cells in response to acute 3-methylcholanthrene treatment. Biochem Pharmacol 1996;51:1427-1436.
69. Fardel O, Morel F, Guillouzo A. P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture. Carcinogenesis 1993;14:781-783.
70. Chin KV, Chauhan SS, Pastan I, Gottesman MM. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1990;1:361-365.
71. Jette L, Beaulieu E, Leclerc JM, Beliveau R. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996;270:F756-F765.
72. Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 2005;18:1-7.
73. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients:a review of pharmacokinetics and clinical experience. Antiviral Ther 2001;6:201-229.
74. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Reader 2001;11:87-98.
75. Cvetkovic RS, Goa KL. Lopinavir/ritonavir:a review of its use in the management of HIV infection. Drugs 2003;63:769-802.
76. Scott JD. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health-System Pharm 2005;62:809-815.
77. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-113.
78. Kashuba AD. Drug-drug interactions and the pharmacotherapy of HIV infection. Topics HIV Med 2005;13:64-69.
79. von Hentig NH, Mueller A, Haberl A. The ATSAQ-1 cohort study;pharmakinetic interactions of atazanavir (ATV) and saquinavir (SAQ) in a ritonavir (RTV) boosted protease inhibitor regimen. XV International AIDS Conference; 2004.
80. de Smet K, Loyer P, Gilot D, Vercruysse A, Rogiers V, Guguen-Guillouzo C. Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem Pharmacol 2001;61:1293-1303.
81. de Smet K, Beken S, Depreter M, Roels F, Vercruysse A, Rogiers V. Effect of epidermal growth factor in collagen gel cultures of rat hepatocytes. Toxicol in Vitro 1999;13:579-585.
82. Ching KZ, Tenney KA, Chen J, Morgan ET. Suppression of constitutive cytochrome P450 gene expression by epidermal growth factor receptor ligands in cultured rat hepatocytes. Drug Metab Dispos Biol Fate Chem 1996;24:542-546.
83. Greuet J, Pichard L, Ourlin JC, Bonfils C, Domergue J, Le Treut P, Maurel P. Effect of cell density and epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture. Hepatology 1997;25:1166-1175.
84. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13:343-368.
85. Moghe PV, Coger RN, Toner M, Yarmush ML. Cell-cell interactiOns are essential for MaIntenance of hepatocyte FunctiOn In collagen gel but not On Matrigel. Biotechnol Bioeng 1997;56:706-711.
86. Moghe PV, Berthiaume F, Ezzell RM, Toner M, Tompkins RG, Yarmush ML. Culture matrix configuration and composition in the maintenance of hepatocyte polarity and function. Biomaterials 1996;17:373-385.
87. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2000;14:177-188.
88. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-539.
89. Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004;309:303-309.
90. Biagini CP, Bender V, Borde F, Boissel E, Bonnet MC, Masson MT, Cassio D, Chevalier S. Cytochrome P450 expression-induction profile and chemically mediated alterations of the WIF-B9 cell line. Biol Cell 2005;98:23-32.
91. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299:620-628.
92. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res 2002;19:773-779.
93. Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates:influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos Biol Fate Chem 2005;33:1679-1687.
94. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164-170.
95. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004;311:476-484.
96. Donato MT, Castell JV, Gomez-Lechon MJ. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices:comparison with other hepatic cellular models. J Hepatol 1999;31:542-549.
97. Omasa T, Kim K, Hiramatsu S, Katakura Y, Kishimoto M, Enosawa S, Ohtake H. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system. Biotechnol Prog 2005;21:161-167.
98. Iwahori T, Matsuura T, Maehashi H, Sugo K, Saito M, Hosokawa M, Chiba K, Masaki T, Aizaki H, Ohkawa K, Suzuki T. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 2003;37:665-673.
99. Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity:systems biology approach and modeling. Drug Discov Today 2004;9:127-135.
100. Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, Ivashchenko AA, Nikolskaya T. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 2003;46:3631-3643.
101. Manga N, Duffy JC, Rowe PH, Cronin MT. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation:consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res 2005;16:43-61.
102. Jones JP, He M, Trager WF, Rettie AE. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos Biol Fate Chem 1996;24:1-6.
103. Bonnabry P, Sievering J, Leemann T, Dayer P. Q uantitative drug interactions prediction system(Q-DIPS):a computer-based prediction and management support system for drug metabolism interactions. Eur J Clin Pharmacol 1999;55:341-347.
104. Langer T, Eder M, Hoffmann RD, Chiba P, Ecker GF. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 2004;337:317-327.
105. Rebitzer S, Annibali D, Kopp S, Eder M, Langer T, Chiba P, Ecker GF, Noe CR. In silico screening with benzofurane-and benzopyrane-type MDR-modulators. Farmaco 2003;58:185-191.
106. Ekins S, Nikolsky Y, Nikolskaya T. Techniques:application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci 2005;26:202-209.
107. Segel I. Enzymes. B iochemical Calculations. Hoboken, NJ:J ohn Wiley & Sons, 1976;pp 208-323.
108. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. Protease inhibitors as inhibitors of human cytochromes P450:high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-111.
109. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-122.
110. Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site:an example of the metabolism of diazepam and its derivatives. Biochem J 1999;340(Pt 3):845-853.
111. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir:the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-296.
112. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88-95.
113. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298:1236-1242.
114. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993;268:14991-14997.
115. Jang SH, Wientjes MG, Au JL. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics:application of computational modeling. J Pharmacol Exp Ther 2003;304:773-780.
116. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [ d-penicillamine2,5]enkephalin. Drug Metab and Dispos Biol Fate Chem 2005;33:287-293.
117. Zahlten RN, Stratman FW. The isolation of hormone-sensitive rat hepatocytes by a modified enzymatic technique. Arch Biochem Biophys 1974;163:600-608.
118. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258.
119. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000;24:129-136.
120. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
121. Eberts FS Jr, Philopoulos Y, Reineke LM, Vliek RW. Triazolam disposition. Clin Pharmacol Ther 1981;29:81-93.
122. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-299.
123. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607.
124. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro:effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-379.
125. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997;61:8-14.
126. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291.
127. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro:inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-791.
128. Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:97-105.
129. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe:effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471.
130. Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994;4:11-20.
131. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
132. Patki KC, von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450:role of CYP3A4 and CYP3A5. Drug Metab Dispos Biol Fate Chem 2003;31:938-944.
133. Greenblatt DJ, von Moltke LL. Drug-drug interactions:clinical perspective. In Rodrigues AD, ed. Drug-Drug Interactions. New York:Marcel Dekker; 2002, pp 565-584.
134. Greenblatt DJ, Wright CE, Von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam and alprazolam clearance:differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237-247.
135. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-143.
136. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
137. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004;76:467-479.
138. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Reduced clearance of triazolam in old age:relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 1983;15:303-309.
139. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-1698.
140. Callachan H, Cottrell GA, Hather NY, Lambert JJ, Nooney JM, Peters JA. Modulation of the GABAA receptor by progesterone metabolites. Proc R Soc London Ser B Biol Sci 1987;231:359-369.
141. McAuley JW, Reynolds IJ, Kroboth FJ, Smith RB, Kroboth PD. Orally administered progesterone enhances sensitivity to triazolam in postmenopausal women. J Clin Psychopharmacol 1995;15:3-11.
142. 3 H]flunitrazepam binding by natural and synthetic progestational agents. Pharmacol Biochem Behav 1993;45:77-83.
143. Fahey JM, Pritchard GA, von Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. J Pharmacol Exp Ther 1998;285:271-276.
144. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics:clinical implications. Clin Pharmacokinet 2003;42:59-98.
145. von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ. Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos Biol Fate Chem 2004;32:800-804.
146. Bent S, Ko R. Commonly used herbal medicines in the United States:a review. Am J Med 2004;116:478-485.
147. Izzo AA. Herb-drug interactions:an overview of the clinical evidence. Fundam Clin Pharmacol 2005;19:1-16.
148. Ernst E. Are herbal medicines effective? Int J Clin Pharmacol Ther 2004;42:157-159.
149. Greenblatt DJ, Patki KC, von Moltke L L, Shader RI. Drug interactions with grapefruit juice:an update. J Clin Psychopharmacol 2001;21:357-359.
150. James, JS. St. John's Warning:Do Not Combine with Protease Inhibitors, NNRTI's. http://www.aids.org/atn/a-337-02.html. 2005.
151. Fugh-Berman A, Ernst E. H erb-drug interactions:review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587-595.
152. Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med 2002;136:616-618.
153. Dietary Supplement Health Education Act of 1994. http://www.fda.gov/opacom/laws/ dshea.html.
154. Dietary Supplements:Questions Answers. US Food Drug Aministration;Center for Food Safety Applied Nutrition; 2001. http://www.cfsan.fda.gov/~dms/ds-faq.html.
155. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003;163:699-704.
156. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products:an analysis of 25 preparations. Am J Clin Nutr 2001;73:1101-1106.
157. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
158. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002;32:451-478.
159. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71:1579-1589.
160. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort:an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601-1608.
161. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
162. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Nat Acad Sci USA 2000;97:7500-7502.
163. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166:R11-R16.
164. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104.
165. Levi F, Pasche C, La Vecchia C, Lucchini F, Franceschi S. F ood groups and colorectal cancer risk. Br J Cancer 1999;79:1283-1287.
166. Delgoda R, Westlake AC. Herbal interactions involving cytochrome P450 enzymes:a mini review. Toxicol Rev 2004;23:239-249.
167. Guyonnet D, Belloir C, Suschetet M, Siess MH, Le Bon AM. Liver subcellular fractions from rats treated by organosulfur compounds from Allium modulate mutagen activation. Mutat Res 2000;466:17-26.
168. Wu CC, Sheen LY, Chen HW, Kuo WW, Tsai SJ, Lii CK. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002;50:378-383.
169. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001;4:176-184.
170. Chen HW, Tsai CW, Yang JJ, Liu CT, Kuo WW, Lii CK. The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats. Br J Nutr 2003;89:189-200.
171. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004;56:1039-1044.
172. Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J, Nakamura K, Kunitomo M. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002;70:2783-2792.
173. Ginkgo. In LaGow B, Ed. PDR for Herbal Medicine. Montvale, NJ:Thomson PDR; 2004, pp. 368-378.
174. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-287.
175. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States:potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
176. Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem Pharmacol 1997;54:1195-1203.
177. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and G inkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-1076.
178. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
179. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly:St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Agin 2005;22:525-539.
180. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-1504.
181. Jöhne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
182. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.
183. Jöhne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
184. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's wort. J Psychopharmacol 2002;16:401.
185. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
186. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000;355:547-548.
187. de Maat MM, Hoetelmans RM, Matht RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St John's wort and nevirapine. AIDS 2001;15:420-421.
188. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004;75:89-100.
189. Blumenthal M. Herbs continue slide in mainstream market:sales down 14 percent. HerbalGram 2003;58:71.
190. Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003;74:170-177.
191. Gallicano K, Foster B, Choudhri S. E ffect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003;55:199-202.
192. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238.
193. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994;3:155-160.
194. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions:a literature review. Drug 2005;65:1239-1282.
195. Evans V. Herbs and the brain:friend or foe? The effects of ginkgo and garlic on warfarin use. J Neurosci Nurs 2000;32:229-232.
196. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933-1934.
197. Meisel C, Jöhne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003;167:367.
198. Hoffman T. Ginkgo, Vioxx and excessive bleeding-possible drug-herb interactions:case report. Hawaii Med J 2001;60:290.
199. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-432.